Logo
x

Search category

Subscribe Now

Severe Eosinophilic Asthma

AstraZeneca's Fasenra Pen (Pre-Filled Auto-Injector) Receives the US FDA's Approval for Severe Eosinophilic Asthma

AstraZeneca's Fasenra Pen (Pre-Filled Auto-Injector) Receives the US FDA's Approval for Severe Eosinophilic Asthma

  • October 4, 2019
GSK Reports Results of Nucala (mepolizumab) in REALITI-A Study for Severe Eosinophilic Asthma

GSK Reports Results of Nucala (mepolizumab) in REALITI-A Study for Severe Eosinophilic Asthma

  • September 30, 2019
GSK's Nucala (mepolizumab) Receives the US FDA's Approval as First Biologic for Severe Eosinophilic Asthma in Children Aged 6-11yrs.

GSK's Nucala (mepolizumab) Receives the US FDA's Approval as First Biologic for Severe Eosinophilic Asthma in Children Aged 6-11yr...

  • September 13, 2019
AstraZeneca Reports Results of Fasenra in BORA P-III Extension trial for the Treatment of Severe Eosinophilic Asthma

AstraZeneca Reports Results of Fasenra in BORA P-III Extension trial for the Treatment of Severe Eosinophilic Asthma

  • September 18, 2018
GSK's Nucala Proves to be Superior than AZ's Fasenra and Teva's Cinqair for the Treatment of Severe Eosinophilic Asthma

GSK's Nucala Proves to be Superior than AZ's Fasenra and Teva's Cinqair for the Treatment of Severe Eosinophilic Asthma

  • September 11, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.